FDA Stalls J&J’s Doribax For Hospital-Acquired Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency needs three more months, company says.
You may also be interested in...
FDA Hearing To Consider Incentives For Antimicrobial Drug Development
Tax incentives for R&D, plus strategies to cap the rise of antimicrobial resistance on the table.
FDA Hearing To Consider Incentives For Antimicrobial Drug Development
Tax incentives for R&D, plus strategies to cap the rise of antimicrobial resistance on the table.
FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting
Data submitted by Theravance/Astellas in response to an October FDA “approvable” letter for the antibiotic could be behind the agency’s decision.